News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

TherOx AMIHOT II Pivotal Trial Meets Endpoints


10/23/2007 11:45:02 AM

WASHINGTON--(BUSINESS WIRE)--TherOx, Inc., a privately held medical device company, announced it has successfully met its endpoints for its pivotal trial, AMIHOT II (Acute Myocardial Infarction with Hyperoxemic Oxygen Therapy), which studied SuperOxygenation Therapy for Acute Myocardial Infarction (AMI) patients. The results were presented today during a late-breaking session at the 19th Annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium, sponsored by the Cardiovascular Research Foundation, in Washington D.C. The data will be submitted shortly to the FDA as part of the company’s Premarket Approval (PMA) application.

Read at BioSpace.com


comments powered by Disqus
TherOx
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES